Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.

Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, Yan Y, Hernandez J, Chen H, Shyr Y, Lim LP, Raymond CK, Lovly CM.

J Thorac Oncol. 2018 Jan;13(1):112-123. doi: 10.1016/j.jtho.2017.09.1951. Epub 2017 Sep 23.

2.

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.

Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, de Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM.

Cancer Res. 2017 Jun 1;77(11):2990-3000. doi: 10.1158/0008-5472.CAN-16-2300. Epub 2017 Apr 17.

3.

A workshop on leadership for senior MD-PhD students.

Meador CB, Parang B, Musser MA, Haliyur R, Owens DA, Dermody TS.

Med Educ Online. 2016 Aug 5;21:31534. doi: 10.3402/meo.v21.31534. eCollection 2016.

4.

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J.

Cancer Res. 2016 Jan 15;76(2):305-18. doi: 10.1158/0008-5472.CAN-15-0717. Epub 2016 Jan 7.

5.

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.

Pirazzoli V, Ayeni D, Meador CB, Sanganahalli BG, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K.

Clin Cancer Res. 2016 Jan 15;22(2):426-35. doi: 10.1158/1078-0432.CCR-15-0620. Epub 2015 Sep 4.

6.

Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors.

Meador CB, Lovly CM.

Nat Med. 2015 Jul;21(7):663-5. doi: 10.1038/nm.3899. No abstract available.

PMID:
26151324
7.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, Ahdesmaki MJ, Ahmed A, Ratcliffe LE, O'Brien EL, Barnes CH, Brown H, Smith PD, Dry JR, Beran G, Thress KS, Dougherty B, Pao W, Cross DA.

Cancer Res. 2015 Jun 15;75(12):2489-500. doi: 10.1158/0008-5472.CAN-14-3167. Epub 2015 Apr 13.

8.

Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling.

Meador CB, Pao W.

Cancer Discov. 2015 Apr;5(4):348-50. doi: 10.1158/2159-8290.CD-15-0221.

9.

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.

Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W.

Mol Cancer Ther. 2015 Feb;14(2):542-52. doi: 10.1158/1535-7163.MCT-14-0723. Epub 2014 Dec 4.

10.

Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W.

Clin Cancer Res. 2014 May 1;20(9):2264-75. doi: 10.1158/1078-0432.CCR-13-1591. Epub 2014 Mar 5. Review.

11.

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.

Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W.

Genome Res. 2013 Sep;23(9):1434-45. doi: 10.1101/gr.152322.112. Epub 2013 Jun 3.

12.

Serological alterations in carcinogen-exposed teleosts: procedures for preparation and analysis of samples from small fish.

Meador CB, Middlebrooks RL, Martin BJ.

Natl Cancer Inst Monogr. 1984 May;65:211-6.

PMID:
6749255
13.

Medical impairments and military effectiveness. I. Criteria of adequate performance: baseline sample.

GERSONI CS, HILMAR NA, MEADOR CB.

U S Armed Forces Med J. 1960 Jun;11:686-98. No abstract available.

PMID:
13827623
14.

Medical standards for full mobilization.

MEADOR CB, HILMAR NA, GERSONI CS.

U S Armed Forces Med J. 1958 Nov;9(11):1605-38. No abstract available.

PMID:
13615902
15.

Veratrum viride in hypertension.

MEADOR CB, McKEE KT, BOONE JA.

J S C Med Assoc. 1950 Oct;46(10):313-5. No abstract available.

PMID:
14779350

Supplemental Content

Loading ...
Support Center